Ubiquigent Limited (“Ubiquigent”), a drug discovery and development company harnessing novel deubiquitinase (DUB) modulators as new therapeutics for areas of high unmet medical need, today announced a strategic partnership with Alleo Labs Corp. (“Alleo”), a pioneer in using artificial intelligence (AI) to develop new therapeutics for neurological diseases.
Male birth control research wins audience over at STAT Madness event
What happens when too many excellent, pioneering researchers enter a room? A little madness. That’s what attendees at the Breakthrough Summit East in New York
March 22, 2024